As lifetime earnings for pharmaceuticals decrease, commercialization expenses increase and payers tighten their belts on reimbursement, life science companies will be faced with shrinking margins over the next few years. In order to maintain basic operating margin levels and continue investing in research and development at current levels, life science manufacturers will be forced to reduce costs by more than $35 billion by 2017, according to results from a new survey of 70 life science organizations from the IMS Institute for Healthcare Informatics.
The pace of annual global spending on oncology medicines — which is approaching the $100 billion threshold — has moderated over the past five years, even as a surge in innovative and targeted therapies has brought new therapeutic options to the growing number of patients being treated for cancer and as survival rates for most tumor types continue to increase, according to a new report released Tuesday by the IMS Institute for Healthcare Informatics.
As lifetime earnings for pharmaceuticals decrease, commercialization expenses increase and payers tighten their belts on reimbursement, life science companies will be faced with shrinking margins over the next few years.
Total spending on U.S. medicines increased 1% on a real per capita basis in 2013, while the use of healthcare services rose for the first time in three years, according to a report by the IMS Institute for Healthcare Informatics.
Total spending on U.S. medicines increased 1% on a real per capita basis in 2013, while the use of healthcare services overall rose for the first time in three years, according to a new report issued today by the IMS Institute for Healthcare Informatics.
Three-in-four pharmaceutical companies are looking to derive greater value from the influx of healthcare information that includes anonymized electronic medical records and other real-world data, according to a report issued by the IMS Institute for Healthcare Informatics on Wednesday. New investments in a range of commercial operations applications — such as customer relationship management, social media or integrated multi-channel marketing solutions — were cited by more than 70% of respondents as a priority.
With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report by the IMS Institute for Healthcare Informatics.
Earlier this year, the IMS Institute for Healthcare Informatics, the research wing of the healthcare industry analysis firm IMS Health, dropped a bombshell when it showed that U.S. spending on drugs fell in 2012, the first time that had happened in 55 years.
The "vast majority" of available mobile apps focused on health and wellness have limited functionality or evidence of value in advancing healthcare provision and outcomes, according to a new report by IMS Health.
The Supreme Court usually has a lot on its plate in any given year, but this year's term included a pretty big case for the pharmaceutical industry: the Federal Trade Commission v. Actavis, which concerned legal settlements between branded and generic drug makers that often occur when the latter attempts to market a generic drug before the former's patents have expired.
A new study by IMS Institute for Healthcare Informatics found that the most wasteful healthcare spending stems from poor adherence to medications and that more responsible use of medications could save the U.S. healthcare system more than $200 billion a year.
The study is notable as it further illustrates the importance of medication adherence and, perhaps more significantly, touts the role that pharmacists can play in helping their patients live healthier lives.
A growing number of patients on Medicaid are filling their prescriptions through Managed Medicaid plans instead of the fee-for-service model as states switch them over in an effort to improve patient care and cut healthcare costs, but the effects remain unclear, according to a new study.
I am the 99%. And thank God for that. But it’s not what you think. This isn’t about radical politics and class warfare. I’m not looking to tax the 1%. I just want them to take better care of themselves. And I’m definitely not the only one. More and more, payers, insurers and big government are all looking at ways to get this group to live a little healthier.
People ages 65 years and older reduced their volume of prescriptions, while those ages 19 to 25 years increased their use of prescription drugs as the healthcare-reform law allowed them to remain on their parents' insurance, according to a new report by IMS Health.